A cholera vaccine is a vaccine that is effective in preventing cholera. Cholera is spread through contaminated food or water. It is not usually spread directly from person to person, but it can be spread through contact with the feces of an infected person. Cholera causes severe diarrhea and vomiting. If it is not treated quickly, it can lead to dehydration and even death. Cholera is caused by Vibrio cholerae and epidemics that are primarily caused by serogroups O1 and O139. Serogroup O1 has two biotypes (El Tor and classical) and both biotypes can further be classified into three serotypes: Ogawa, Inaba and Hikojima. V. cholerae O1 Hikojima is an unstable form and rarely occurs in nature. The recommended cholera vaccines are administered orally to elicit a protective local mucosal immune response in the gut, which was poorly achieved with the injectable vaccines that were used until the 1970s. The first effective oral cholera vaccine was Dukoral, developed in Sweden in the 1980s. For the public health use of modern cholera vaccines in developing countries, it is important to distinguish between endemic and epidemic cholera. For the control of epidemic cholera, selective vaccination of populations at a definably high risk of an epidemic, or reactive vaccination shortly after the onset of the epidemic, can be considered.
Market Dynamics:
Increasing prevalence of cholera is expected to drive the growth of the Zambia cholera vaccines market over the forecast period. For instance, on January 16, 2024, according to data published by U.S. EMBASSY IN ZAMBIA, since October 2023, in Zambia, there have been 8,276 cumulative cholera cases, with 333 deaths, and a case fatality rate of 4% which is four times the World Health Organization (WHO) threshold.
Key Features of the Study:
Detailed Segmentation:
Zambia Cholera Vaccines Market - Segmentation
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients